MitoSciences Inc. and University of Oregon Enter Into Biotechnology Deal

MitoSciences Inc., a biotechnology company, and the University of Oregon announced this month the completion of an exclusive commercial license for a portfolio of monoclonal antibodies.
The terms of the agreement include the University of Oregon will continue its equity position in the company and receive royalties. MitoSciences was formed in 2003 by Roderick Capaldi, a researcher at the University of Oregon’s (UO) Institute of Molecular Biology, and Michael Marusich, director of the university’s Monoclonal Antibody Facility. The company employs more than 20 employees at the UO Riverfront Research Park.

↑ Back to TechConnect News™

Event Spotlights

Austin, TX, December 1-3, 2015
Austin, TX, December 1-3, 2015

Annual Meeting

TechConnect World 2015
Washington, DC, May 22-25, 2016